JP Morgan Chase
SLNO

JP Morgan Chase’s Soleno Therapeutics SLNO Stock Holding History

JP Morgan Chase’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-156,800
Closed -$11.2M – 7590
2025
Q1 		$11.2M Buy
156,800
+155,800
+15,580% +$7.59M ﹤0.01% 2436
2024
Q4 		$45K Buy
+1,000
New +$51.8K ﹤0.01% 6053

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

JP Morgan Chase's SLNO Position: Q1 2026 in Review

JP Morgan Chase reduced its Soleno Therapeutics (SLNO) stake by 55% in Q1 2026, selling an estimated $2.51M and leaving 51,480 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4283.

JP Morgan Chase first reported a position in SLNO in Q4 2017 and has held it in 25 quarters since. The position peaked at $27.5M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • JP Morgan Chase held 51,480 shares of Soleno Therapeutics worth $1.57M as of Q1 2026.
  • JP Morgan Chase sold 64,037 Soleno Therapeutics shares in Q1 2026, an estimated $2.51M.
  • Soleno Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4283 holding.
  • JP Morgan Chase first reported a position in Soleno Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • JP Morgan Chase's Soleno Therapeutics position peaked at $27.5M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.